Clinical trials: Malaria, completed
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district)…
- Trial name
- COMBAT (NCT05052502)
- Testing
- Case Management and Follow-up, Reactive focal mass drug administration (rfMDA)
- Where
- Thailand
- Volunteers
- 14,977 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Falciparum, Hookworm Infections
Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma
The aim of this study is to investigate the change in iron metabolism in relation to malaria and helminth infections using a stable isotope technique.
- Conditions
- Malaria, Falciparum, Hookworm Infections, Schistosoma Haematobium
- Trial name
- NCT01163877
- Testing
- Fe-57 orally, Fe-58 intravenously
- Where
- Côte d’Ivoire
- Volunteers
- 43 people
- Sponsor
- Swiss Federal Institute of Technology
Falciparum Malaria
Study to Investigate the Induction of an Protective Immune Response to Malaria
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
- Trial name
- NCT00442377
- Testing
- exposure to malaria sporozoites
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Dynamics of Subclinical Malaria: Preliminary Study
This is a short longitudinal preliminary study that aims to describe the dynamics of low-density subclinical malaria to support the final study design of a subsequent matched cohort study.
- Trial name
- NCT03483571
- Where
- Burma
- Volunteers
- 2,970 people, healthy volunteers welcome
- Sponsor
- Duke University
Malaria
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
- Trial name
- NCT02601716
- Testing
- PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence
In the past decade, massive scale-up of insecticide-treated nets (ITN) and indoor residual spraying (IRS), together with the introduction of artemisinin-combination treatments, have led to substantial reductions in malaria…
- Trial name
- LLML (NCT02392832)
- Testing
- Fourstar® granule, 90 day and 180 day briquettes Bti/Bs
- Where
- Kenya
- Volunteers
- 240,000 people
- Sponsor
- University of California, Irvine
Malaria
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
The present trial will evaluate safety and tolerability as well as the vaccine-induced humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and infants who receive doses of 1.8x10^6, 9.0x10^5…
- Trial name
- NCT02613520
- Testing
- PfSPZ Vaccine, Normal Saline, PfSPZ Challenge (for CHMI)
- Where
- Tanzania
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria,Falciparum
"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"
This clinical trial evaluates the advantage of prolonging the therapeutic life span of Artemether-lumefantrine from 3 days to 6 days, and addition of single low dose of Primaquine 0.25mg/kg.
- Trial name
- ALU-PQ (NCT03241901)
- Testing
- Artemether-Lumefantrine Tab 20-120mg, Primaquine Phosphate 0.25 mg/kg
- Where
- 2 sites in Tanzania
- Volunteers
- 280 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Childhood Mortality
Mortality Reduction After Oral Azithromycin: Morbidity Study
The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic…
- Trial name
- MORDORMorb (NCT02048007)
- Testing
- Azithromycin
- Where
- 6 sites in United States, Malawi and 3 more
- Volunteers
- 72,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Antioxidant Micronutrients in Malaria
In the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in Africa. An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5…
- Trial name
- AMM (NCT01152931)
- Testing
- Amodiaquine + Artesunate, Lumefantrine + Artemether, Artesunate + vitamin A
- Where
- 2 sites in Nigeria
- Volunteers
- 10 people
- Sponsor
- University of Lagos, Nigeria
Malaria,Falciparum
Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania
This is an age de-escalation, dose-escalation open label randomised trial studying the safety and immunogenicity of RH5.1/Matrix-M, administered intramuscularly in healthy adults, young children and infants in Tanzania
- Trial name
- NCT04318002
- Testing
- RH5.1/Matrix-M
- Where
- Tanzania
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811882)
- Testing
- KAE609 (Cipargamin), SoC (Coartem), INE963
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines
The purpose of this study is to determine whether artemether + lumefantrine is as effective as chloroquine + sulfadoxine pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria
- Trial name
- NCT00229775
- Testing
- artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine
- Where
- 3 sites in Philippines
- Volunteers
- 560 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Malaria Vaccine in Children in Mali
This study will test an experimental vaccine called AMA1-C1 in children to see if it is safe and if it reduces episodes of malaria parasitemia (parasites in the blood) in children exposed to malaria.
- Trial name
- NCT00341250
- Testing
- AMA1-C1/Alhydrogel Malaria Vaccine
- Where
- 2 sites in Mali
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.
- Trial name
- NCT00344006
- Testing
- chlorproguanil-dapsone-artesunate, artemether-lumefantrine
- Where
- 9 sites in Burkina Faso, Ghana and 3 more
- Volunteers
- 1,395 people
- Sponsor
- GlaxoSmithKline
Malaria
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants
This will be a double-blinded randomized controlled phase III trial of 300 HIV uninfected pregnant women and the children born to them. The study interventions will be divided into two phases.
- Trial name
- PROMOTE-BC1 (NCT02163447)
- Testing
- Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy, 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
- Where
- Uganda
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.
Healthy Volunteers
Malaria: Relative Bioavailability and Food Effect of DSM265
Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
- Trial name
- NCT03637517
- Testing
- DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Sickle Cell Anemia in Children, Malaria
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
Sickle Cell Anaemia (SCA) is an inherited disease that makes the body produce red blood cells with abnormal sickle-shaped cells. The sickle-shaped cells are rigid, not flexible and break up easily resulting in anaemia.
- Trial name
- CHEMCHA (NCT04844099)
- Testing
- Dihydroartemisinin Piperaquine
- Where
- 3 sites in Malawi, Uganda
- Volunteers
- 723 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Impact of Malaria on Pregnant Women in Ouelessebougou, Mali
Background: Malaria is a serious disease. It is passed by infected mosquitoes. In many parts of Africa, malaria continues to be the main cause of death in young children and pregnant women.
- Trial name
- NCT02974608
- Where
- Mali
- Volunteers
- 7,691 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites
Malaria affects around 515 million people each year, about a million of whom die from the disease. It is a major problem for those who live in affected areas as well as for travellers to affected areas.
- Trial name
- NCT00890760
- Testing
- AdCh63 ME-TRAP, MVA ME-TRAP, Sporozoite challenge
- Where
- United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.